Pakistan’s problem with diabetes – with 7 million diabetics

pharmafile | March 20, 2017 | News story | Medical Communications, Sales and Marketing Pakistan, Sanofi, diabetes 

Pakistan is facing an increasing problem with people suffering from diabetes. At a recent conference, the 4th International Diabetes Conference, it was revealed that approximately 7 million people are now diabetic.

The worrying problem is that, of those 7 million, 1.6 million were children and this points towards a problem that could grow, as the generational issues develop as it ages, if changes are not made to improve the health of the population. Speakers at the conference predicted that by 2040, Pakistan is projected to have 14.4 million diabetics and will likely rise to 8th position, in countries that have the highest proportion of people with the condition.

The 7 million estimated diabetics occur in a population of an approximate total of 195 million people. Speakers at the conference pushed for more screenings for those who are at a higher risk of suffering from diabetes.

The advice from experts was to follow the International Diabetes Federation slogan of Eat less, walk more”. With one expert claiming that if a person walks 10,000 steps per day, from age 22 onwards, he will never get chronic disease. Though the latter part of the claim may be dubious, it would certainly help improve overall health.

The conference was sponsored by Sanofi and included numerous speakers from the company. Sanofi is a major producer of diabetes medication and extending its influence into Pakistan, as the US market becomes increasingly competitive, is a way of hedging its market losses. Sanofi is currently the 5th largest company in Pakistan.

Ben Hargreaves

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

FDA approves new insulin pump and algorithm software for enhanced automated insulin delivery

The US Food and Drug Administration (FDA) has announced that it has cleared the Beta …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Latest content